Nanopharmaceuticals Market Report 2026

The nanopharmaceuticals market size has grown rapidly in recent years. It will grow from $112.49 billion in 2025 to $132.73 billion in 2026 at a compound annual growth rate (CAGR) of 18%. The growth in the historic period can be attributed to limited nanotechnology applications in early pharmaceutical development, reliance on conventional drug delivery systems, growing research in oncology and neurology, regulatory approvals for initial nanopharmaceuticals, increasing awareness of targeted therapies.

The nanopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $254.37 billion in 2030 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to advancement in liposomal and polymeric micelle technologies, growth of nanoemulsions and solid lipid nanoparticles, increasing adoption of personalized medicine, expansion of research in cardiovascular and anti-infective applications, rising investment in scalable nanopharmaceutical manufacturing. Major trends in the forecast period include rising adoption of targeted nanopharmaceutical therapies in oncology, growth in nano-based drug delivery systems for neurology, increased focus on anti-inflammatory and anti-infective applications, expansion of pulmonary and injectable nanopharmaceutical formulations, development of lipid-based and polymeric nanocarriers with enhanced bioavailability.

The increasing prevalence of chronic diseases is expected to drive the growth of the nanopharmaceuticals market in the coming years. Chronic diseases are long-term conditions that generally require continuous medical care and management over many years or throughout a person’s lifetime, including cancer, diabetes, heart disease, asthma, and other similar illnesses. The rising incidence of chronic diseases is driven by factors such as unhealthy eating habits, insufficient physical activity, tobacco use, excessive alcohol intake, genetic susceptibility, and environmental factors. Nanopharmaceuticals are applied in the treatment of chronic diseases by enabling targeted drug delivery, improving bioavailability, allowing controlled drug release, minimizing side effects, and supporting advanced combination therapies, thereby enhancing treatment effectiveness and patient outcomes. For example, in April 2025, according to the Centers for Disease Control and Prevention, a US-based federal agency, data from 2023 indicated that approximately 76.4% of US adults reported having at least one of 12 selected chronic conditions, while 51.4% reported having multiple chronic conditions. Therefore, the increasing burden of chronic diseases is contributing to the growth of the nanopharmaceuticals market.

Major companies operating in the nanopharmaceuticals market are increasingly adopting strategic partnership approaches to strengthen their capabilities and market presence. Strategic partnerships involve companies collaborating by combining their respective strengths and resources to achieve shared goals and mutual success. For instance, in April 2024, Nanoform Finland Plc, a Finland-based nanoparticle medicine company, partnered with CBC Co. Ltd., a Japan-based development-oriented trading company, to explore opportunities related to Nanoform’s advanced nanomedicine engineering technologies. This strategic collaboration represents a significant step toward leveraging advanced nanotechnology to improve medicines for patients globally.

In August 2025, AbbVie, a US-based pharmaceutical and biopharmaceutical company, acquired Capstan Therapeutics for an undisclosed amount. Through this acquisition, AbbVie enhanced its immunology pipeline and gained in vivo cell-engineering capabilities. Capstan Therapeutics is a US-based biotechnology company that specializes in a targeted lipid nanoparticle (tLNP) nanopharmaceutical platform, including an mRNA-based in vivo CAR-T therapy candidate, CPTX2309.

Major companies operating in the nanopharmaceuticals market are Selecta Biosciences Inc., Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Par Pharmaceutial Inc., Samyang Biopharm Corporation.

North America was the largest region in the global nanopharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nanopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the nanopharmaceuticals market by increasing the cost of imported nanomaterials, advanced polymers, and specialized manufacturing equipment. Segments such as liposomes, polymeric micelles, and nanoemulsions are most affected, particularly in North America, Europe, and Asia-Pacific regions like China and India. These tariffs have led to higher production costs and potential delays in drug development. However, they have also encouraged local sourcing, domestic manufacturing, and innovation in cost-efficient nanocarrier technologies.

The nanopharmaceuticals market research report is one of a series of new reports that provides nanopharmaceuticals market statistics, including nanopharmaceuticals industry global market size, regional shares, competitors with a nanopharmaceuticals market share, detailed nanopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the nanopharmaceuticals industry. This nanopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nanopharmaceuticals are a category of pharmaceutical drugs that employ nanotechnology to enhance the delivery, targeting, and effectiveness of therapeutic agents. These drugs are engineered at the nanoscale, typically ranging from 1 to 100 nanometers, and are designed to improve drug solubility, stability, bioavailability, and targeted delivery to specific cells or tissues. Nanopharmaceuticals represent an advanced approach in modern medicine, offering the potential for more accurate, efficient, and safer treatments across a broad range of diseases.

The primary types of nanopharmaceuticals include liposomes, polymeric micelles, solid lipid nanoparticles, microemulsions, nanoemulsions, and others. Liposomes are small, spherical vesicles composed of phospholipids that can encapsulate drugs, thereby enhancing their delivery to targeted cells or tissues. They help protect drugs from degradation and can improve absorption. These medicines can be administered through multiple routes, including oral, injectable, topical, pulmonary, and others. Their applications span oncology, neurology, anti-inflammatory, anti-infective, cardiovascular, and other areas, and they are supplied to end users such as hospitals and clinics, specialty pharmacies, research institutions, and others.

The nanopharmaceuticals market consists of sales of dendritic nanoparticles, quantum dots, micellar nanoparticles, and gene delivery systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.